TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02402647

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Rehabilitation and Exposure/Sorting Treatment (CREST)
Description: Compensatory Cognitive Training is a manualized, low-tech, cognitive training intervention designed to target cognitive impairments common in people with psychiatric illness. The CCT modules specifically selected for CREST map onto known areas of HD neurocognitive deficits or weakness and include training in prospective memory, prioritizing, problem solving, planning, and cognitive flexibility.~Symptoms of acquiring and saving are themselves avoidance behaviors that are performed to avoid internal distress related to negative thoughts and emotions. Avoidance serves to reduce distress related to the beliefs regarding the necessity and utility of possessions. In the CREST condition, the second part and the majority of treatment is dedicated to exposure therapy (ET) for discarding and not acquiring while in the control condition, the entire treatment will consist of ET.
Study: NCT03970642

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video directly observed therapy
Description: The intervention group will receive individualized text reminders on their phone prior to each dose of their depression medicine. They will be requested to use the VDOT smartphone app to make a video recording of each medication dose ingested during the 3 month study period following their first visit. The app will automatically upload the video to a HIPAA compliant server. Research staff will regularly monitor videos using a password protected website and document each medication dose.
Study: NCT04543825

Intervention type: DEVICE
Intervention: Cardiopulmonary exercise testing
Description: Subjects will perform cardiopulmonary exercise testing which consists of biking on a cycle ergometer (recumbant stationary bicycle) while breathing through a mouthpiece or mask to measure the oxygen and carbon dioxide in the subject's breath. We will also do impedance cardiography, an FDA-approved test to check how the heart functions during exercise. For this test we will attach 6 electrodes (total) to the chest and back (similar to an EKG), so that we can measure the quantity of blood coming out of the heart on every heartbeat. Each evaluation will also include cardiac testing looking for coronary artery disease (CAD).
Study: NCT03059433

Intervention type: OTHER
Intervention: AVID Intervention
Description: Advancement via Individual Determination (AVID) is a college preparatory program that participating high schools have available to students.
Study: NCT01066260

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic formulation
Description: Twice a day for 24 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Twice a day for 24 days
Study: NCT04449744

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MySafeRx Inspire Plus
Description: The MySafeRx™ platform is a combination of several key components, including daily videoconferencing check-ins with motivational interviewing-based recovery coaching, text-messaging reminders, secure storage of buprenorphine/naloxone medication within a secure electronic pill dispenser, and a standardized protocol for supervising self-administration of medication via videoconferencing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MySafeRx Inspire Flex
Description: The MySafeRx™ platform is a combination of several key components, including daily videoconferencing check-ins with motivational interviewing-based recovery coaching, text-messaging reminders, secure storage of buprenorphine/naloxone medication within a secure electronic pill dispenser, and a standardized protocol for supervising self-administration of medication via videoconferencing. Based on clinical need, the participant may be assigned an electronic pill dispenser for the duration of the study by their clinical team.
Study: NCT00903721

Intervention type: DRUG
Intervention: mometasone furoate
Description: Metered-dose spray type suspension containing 50 μg mometasone furoate per spray. 2 sprays per nostril twice daily (total daily dose 200 μg)~Duration: up to 6 months

Intervention type: DRUG
Intervention: mometasone furoate
Description: Metered-dose spray type suspension containing 50 μg mometasone furoate per spray. 2 sprays per nostril twice daily (total daily dose 200 μg)~Duration: up to 6 months
Study: NCT04202575

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tube clamping
Description: Clamping of the tube between the additional and standard venous reservoir
Study: NCT02537899

Intervention type: DRUG
Group type: OTHER
Intervention: NeuroAiD
Study: NCT04733300

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based College for Young Adults
Description: MB-College (MBC) is a 9-week, 9 session curriculum providing systematic and intensive training in mindfulness meditation practices, applied to health behaviors relevant to young adults (18-29). The curriculum, which is based on the manualized and standardized Mindfulness-Based Stress Reduction (MBSR) curriculum is designed to teach participants how to integrate and apply mindfulness in their everyday lives to the range of challenges arising from medical and psychological conditions and life stresses.~MBC will be administered live, online via a video conferencing platform to participants enrolled in the active arms of the study: (1) standard dose MBC and (2) low-dose MBC. Standard dose MBC meets once a week for 2.5 hours for 9 weeks, while low-dose MBC meets for 1.5 hours per week for 9 weeks. There is an all-day retreat that takes place around week six of the program that applies to both MBC programs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based College for Young Adults
Description: MB-College (MBC) is a 9-week, 9 session curriculum providing systematic and intensive training in mindfulness meditation practices, applied to health behaviors relevant to young adults (18-29). The curriculum, which is based on the manualized and standardized Mindfulness-Based Stress Reduction (MBSR) curriculum is designed to teach participants how to integrate and apply mindfulness in their everyday lives to the range of challenges arising from medical and psychological conditions and life stresses.~MBC will be administered live, online via a video conferencing platform to participants enrolled in the active arms of the study: (1) standard dose MBC and (2) low-dose MBC. Standard dose MBC meets once a week for 2.5 hours for 9 weeks, while low-dose MBC meets for 1.5 hours per week for 9 weeks. There is an all-day retreat that takes place around week six of the program that applies to both MBC programs.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Education for Young Adults
Description: The health education control group will receive young adult-specific online health resources offered through www.youngwomenshealth.org and www.youngmenshealthsite.org. Both websites provide resources to improve mental and physical health, and include opportunities to ask health questions, and learn ways to improve mental and physical well-being.
Study: NCT00100178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofeteil (MMF)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofeteil (MMF)
Study: NCT06745986

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided fascia iliaca compartment block ( bupivacaine 0.25% )
Description: Fascia iliaca compartment block by bupivacaine 0.25% in a total volume of 40 ml.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Anesthesia (bupivacaine)
Description: spinal anesthesia by 2.5 ml bupivacaine 0.5%
Study: NCT00100178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclizumab (DZB)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control for Mycophenolate mofeteil (MMF)
Description: Placebo pills taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo control for Daclizumab (DZB)
Description: saline intravenous infusions
Study: NCT04656340

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: non-medication, non-interventional therapies
Description: non-medication, non-interventional therapies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: non-medication, non-interventional therapies
Description: non-medication, non-interventional therapies
Study: NCT02402647

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure Therapy (ET)
Description: The investigators propose to use a robust control condition, ET, with the same frequency and amount of therapist contact as CREST. Twenty-six weekly, individual ET sessions (6 months) will be delivered. The control group will receive ET for all 26 sessions and no cognitive training. As in CREST, the ET sessions will be manualized and copies utilized during session by both the patient and therapist.
Study: NCT00100178

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control for Daclizumab (DZB)
Description: saline intravenous infusions
Study: NCT03458962

Intervention type: GENETIC
Intervention: Genetic Enrollees
Description: Identification of new genetic diagnoses in children with multiple congenital anomalies, developmental delay, autism, seizures, intellectual disabilities, neurodegenerative disorders and metabolic illness. Samples and data will be stored in a pediatric biorepository. A subset of samples will undergo genetic/genomic analysis.
Study: NCT02477839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: Active Substance: Lacosamide Pharmaceutical Form: Syrup Concentration: 10 mg/mL Route of Administration: oral

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Active Substance: Placebo Pharmaceutical Form: Syrup Concentration: N/A Route of Administration: oral
Study: NCT01285453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vadimezan
Study: NCT02781779

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Silverlon®
Description: Silverlon wound dressings

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AQUACEL® AG
Description: AQUACEL® AG wound dressings
Study: NCT02626767

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Novel high-intensity interval exercise training
Description: Please see information already included in the 'intervention' arm description.
Study: NCT02268955

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Ibuprofen
Description: Intravenous ibuprofen will be administered for treatment of pain in adults presenting to the ED with biliary colic

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline will be administered to the placebo group
Study: NCT01287078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine Inhalation Solution
Description: sterile, clear, colorless, preservative-free solution of cyclosporine (USP) in propylene glycol developed specifically for administration by oral inhalation.
Study: NCT02216786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2014
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2014
Description: Oral tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: Oral tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Im injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Im injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Im injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Im injection
Study: NCT02121574

Intervention type: DEVICE
Intervention: Zero flux and ingestible thermometers
Study: NCT02646592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alfentanil
Description: Bolus of alfentanil 10 µg/kg 5 minutes before skin incision
Study: NCT04274387

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Stress Reduction(MBSR)
Description: A structural program focusing on the practice about attending to the current moment with non-judgmental attitude
Study: NCT01173757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04995274
Description: Single dose of up to 5 mg PF-04995274, delivered in solution on study day 1
Study: NCT03701126

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.25% Injectable Solution
Description: Dose 1ml /kg of patient body weight

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.25% Injectable Solution
Description: Dose 1ml /kg of patient body weight

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultra-sound guidance
Description: using superficial high frequency probe to guide regional anesthesia
Study: NCT01955356

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scratching
Description: Endometrial biopsy
Study: NCT02646592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sevoflurane or propofol
Study: NCT02109393

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MIRT
Description: It consists of a 4-weeks physical therapy which entails four daily sessions for five days. All treatments are performed in aerobic condition. The duration of each session, including recovery periods, is about one hour. The first session consists of a one-to-one session with physical therapist. The second session includes aerobic and repetitive exercises to improve balance and gait using different devices: a posturographic platform with visual cues, cycloergometer, treadmill-plus. The third is a session of occupational therapy. The last session includes one hour of speech therapy.~All patients undergo 20-minutes treadmill-plus training per day, 5 times a week, for 4 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MIRT+Lokomat
Description: It consists of a 4-weeks physical therapy which entails four daily sessions for five days. All treatments are performed in aerobic condition. The duration of each session, including recovery periods, is about one hour. The first session consists of a one-to-one session with physical therapist. The second session includes aerobic and repetitive exercises to improve balance and gait using different devices: a posturographic platform with visual cues and cycloergometer. The third is a session of occupational therapy to improve autonomy in activities of daily life. The last session includes one hour of speech therapy. All patients undergo 20-minutes Lokomat® training per day in spite of treadmill-plus.
Study: NCT03701126

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultra-sound guidance
Description: using superficial high frequency probe to guide regional anesthesia
Study: NCT04349384

Intervention type: PROCEDURE
Intervention: Colorectal resection
Description: Colon or rectal resection for colorectal adenocarcinoma

Intervention type: PROCEDURE
Intervention: Colorectal resection
Description: Colon or rectal resection for colorectal adenocarcinoma
Study: NCT03331328

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: MonaLisa Touch
Description: MonaLisa Touch is a fractional CO2 laser that has been specially designed with the DEKA pulse to stimulate vaginal tissue. It is delivered in a very precise manner and results in the synthesis of collagen and stratification of the vaginal epithelium with improvement of the vaginal pH and moisturization of the vaginal tissue due to increased blood flow and turgidity of the ground substance from the synthesis of the proteoglycans, hyaluronic acid and collagen.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MonaLisa Touch
Description: MonaLisa Touch is a fractional CO2 laser that has been specially designed with the DEKA pulse to stimulate vaginal tissue. It is delivered in a very precise manner and results in the synthesis of collagen and stratification of the vaginal epithelium with improvement of the vaginal pH and moisturization of the vaginal tissue due to increased blood flow and turgidity of the ground substance from the synthesis of the proteoglycans, hyaluronic acid and collagen.
Study: NCT00389519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ramipril
Description: once a day oral ramipril capsules given for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ramipril
Description: once a day oral ramipril capsules given for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ramipril
Description: once a day oral ramipril capsules given for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: once a day oral placebo capsule for 4 weeks
Study: NCT01045317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04776548
Description: single intravenous or oral administration of 0.1mg PF-04776548.
Study: NCT03528954

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Those who received intravenous propofol
Study: NCT03425539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucerastat
Description: Hard gelatin capsules containing 250 mg of lucerastat and inactive excipients; 1000 mg (4 capsules) twice daily (b.i.d.); dose adjusted for renal function.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules are identical in appearance to the lucerastat capsules, and contain inactive excipients; 4 capsules b.i.d.; dose adjusted for renal function.
Study: NCT01076218

Intervention type: DEVICE
Intervention: FreeStyle Navigator Continuous Glucose Monitoring System Version 1.5
Description: This is not an interventional study. Subjects must maintain their own diabetes treatment regimen throughout the study duration.
Study: NCT03181724

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Decision Aid
Description: Cohort I will be managed with a decision aid (henceforth DA), and Cohort II will be managed without one. The patients in Cohort I will receive the DA, which they can complete in a separate room and take home. The decision aids include information on the disease/condition, treatment options, benefits, risks, scientific uncertainties, and probabilities of potential outcomes tailored to the patient's health risks factors. Additionally, it includes values clarifications such as describing outcomes in functional terms, asking patients to consider which benefits and risks matter most to them, and guidance in the steps of decision making and discussing their decision with family/friends. It is interactive and dynamic, helping patients clarify their preferences and come to a decision that feels best to them.
Study: NCT03254329

Intervention type: OTHER
Intervention: Assessment of human milk nutrient composition
Description: Observational study to measure nutrients in human milk during lactation and their relationship to maternal and infant nutritional status.

Intervention type: OTHER
Intervention: Assessment of human milk nutrient composition
Description: Observational study to measure nutrients in human milk during lactation and their relationship to maternal and infant nutritional status.

Intervention type: OTHER
Intervention: Assessment of human milk nutrient composition
Description: Observational study to measure nutrients in human milk during lactation and their relationship to maternal and infant nutritional status.

Intervention type: OTHER
Intervention: Assessment of human milk nutrient composition
Description: Observational study to measure nutrients in human milk during lactation and their relationship to maternal and infant nutritional status.
Study: NCT04161755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered 6 weeks post-tumor resection (+/- 2 weeks)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RO7198457
Description: RO7198457 will be administered 9 weeks post-tumor resection (+/- 2 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX
Description: mFOLFIRINOX regimen will be administered 21 weeks post-tumor resection (+/- 2 weeks)
Study: NCT03547817

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent negative pressure device
Description: Pressure levels of 0 mmHg, -10 mmHg, -20 mmHg, -40 mmHg and -60 mmHg will be tested, with washout periods of 5 minutes between the different pressure levels
Study: NCT02272894

Intervention type: PROCEDURE
Intervention: Dissection of the Superior Mesenteric Vein Lymph Node
Description: 14v lymph node dissection
Study: NCT02121041

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Amlodipine 5 mg or 10 mg
Study: NCT03561753

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group A (the standard 2HRZE/4HR regimen）
Description: The standard six-month regimen is eight weeks of daily treatment with isoniazid, rifampin, ethambutol, and pyrazinamide followed by sixteen weeks of isoniazid and rifampin. The six-month regimen is the standard regimen for the treatment of drug-susceptible tuberculosis recommended by WHO.
Study: NCT01391013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir(DRV)
Description: Oral administration of tablet DRV 800 mg (2 tablets of 400 mg) once daily at the same time, within 30 minutes after food for 48 weeks
Study: NCT04293432

Intervention type: DRUG
Intervention: Drugs, Generic
Description: All drugs having ≥10 TdP cases reported in the FAERS database
Study: NCT02990702

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided retroclavicular block
Description: Ultrasound guided retroclavicular block for forearm or hand surgery

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided retroclavicular block
Description: Ultrasound guided retroclavicular block for forearm or hand surgery

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided coracoid infraclavicular block
Description: Ultrasound guided infraclavicular block for forearm or hand surgery

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided coracoid infraclavicular block
Description: Ultrasound guided infraclavicular block for forearm or hand surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Study: NCT03422133

Intervention type: OTHER
Intervention: Patient-oriented, personalized risk communication eHealth application
Description: The application features simple and consistent design, large well-lit buttons that tolerate tremor, and simple language. The process will be applied in preoperative clinics at The Ottawa Hospital (TOH), where patients will be asked to provide their personal health history through a series of questions already used on our TOH preoperative health screener. These values will then populate the NSQIP Universal Risk Calculator, which we have calibrated to TOH data, to generate personalized risks of mortality, serious complications, and hospital length of stay. These risk estimates will be communicated directly to the patient using absolute risk estimates represented pictorially (best practice for risk communication to patients). Risk estimates will also be provided to the patient's clinician.